Ziphius Vaccines and UZ Ghent Establish Unique Collaboration for GMP Manufacturing of saRNA-Based Vaccines
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing vaccines and therapeutics based on self-amplifying RNA (saRNA), and UZ Ghent today announce that they have entered a public-private collaboration for the scale up and manufacturing of prophylactic self-amplifying RNA vaccines based on GMP (Good Manufacturing Practice) standards.
The collaboration is a first in Europe where a university hospital produces GMP grade prophylactic saRNA vaccines for an industry partner. The partnership fits the Belgian government’s R&D Biopharma initiative where collaboration and coordination are encouraged to accelerate Belgium’s involvement in selected innovative platforms such as mRNA. Via this collaboration Ziphius and UZ Ghent aim to contribute to strengthening Belgium’s position as a leading global biopharma hub and invest in preparedness for future disease threats (Pandemic Preparedness).
Read the full press release here: https://ziphius.org/press-release/ziphius-vaccines-and-uz-ghent-establish-unique-collaboration-gmp-manufacturing-sarna
Link to the Kanaal Z interview and video: https://kanaalz.knack.be/nieuws/uz-gent-en-ziphius-ontwikkelen-nieuwe-generatie-vaccins/video-normal-1905181.html?cookie_check=1665304759